About 113,000 results
Open links in new tab
  1. Tau (AT8); Phospho Tau (Ser 202, Thr 205) - ALZFORUM

    Feb 6, 2024 · Hyperphosphorylated tau polymerizes into paired helical filaments, which aggregate to form neurofibrillary tangles, one of the defining lesions of Alzheimer’s disease. Recognizes paired …

  2. Triple Trouble: New Knock-in Turbocharges Tauopathy

    May 1, 2025 · They accumulated hyperphosphorylated tau in their brains and lost synapses by approximately 15 months of age, but they had no tau oligomers capable of seeding aggregates. …

  3. 301 Moved Permanently

    Moved PermanentlyThe document has moved here.

  4. Tau (PHF-1) | ALZFORUM

    Feb 5, 2024 · Recognizes tau doubly phosphorylated at serines 396 and 404 Immunoreactivity seen in Alzheimer's disease and other tauopathies but not controls Used to assess the progression of tau …

  5. ApoE3 Christchurch Clings Tightly to Tau, Averting Tangles

    Feb 1, 2025 · To find out, the scientists turned to surface plasmon resonance, a technique that quantifies molecular interactions in real time. It showed that ApoE3Ch clings onto tau monomers …

  6. LY3954068 | ALZFORUM

    Nov 25, 2024 · LY3954068 is a small interfering RNA (siRNA) that targets expression of the microtubule-associated binding protein tau. No information is available about the makeup of LY3954068.

  7. Tau (CP-13) - ALZFORUM

    Feb 7, 2024 · This monoclonal antibody, generated against paired helical filaments (PHFs) isolated from Alzheimer’s brains, recognizes tau phosphorylated at serine 202. Recognizes tau phosphorylated at …

  8. A Tale of Two T Cells—Slowing Tau Spread, Shredding White Matter

    Jul 11, 2025 · With T cells sidelined in these CD8 knockouts, tau pathology went on the offensive. By 30 weeks of age, phospho-tau had spread deeper into the brain than in CD8-intact controls (image …

  9. Plasma p-Tau217 Flags Alzheimer’s Pathology in Other Disorders

    Feb 20, 2025 · Plasma p-Tau217 detects AD co-pathology in FTD patients with high accuracy. FTD patients with AD co-pathology performed worse on memory tests. The marker identifies people who …

  10. Gosuranemab - ALZFORUM

    Full trial results, published after peer review, confirmed that gosuranemab reduced CSF unbound N-terminal tau fragments by 98 percent, but did not change other exploratory biomarkers, or primary or …